Dirk van Esser, MD, discusses safety with KRd in the EMN15/HOVON147 trial and how to select patients with high-risk smoldering myeloma for treatment.
Dirk van Esser, MD, PhD Candidate
Advertisement
Articles by Dirk van Esser, MD, PhD Candidate
Dirk van Esser, MD, discusses long-term EMN15/HOVON147 data for KRd vs Rd in high-risk smoldering multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
2
AI Enables Enhanced Decision Making and New Opportunities in Orthopedic Oncology
3
Dr Encinas Mayoral on an AI-Designed BCMA/FcRL5-Targeting TRiTE in Multiple Myeloma
4
Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer
5